A Phase II Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Progesterone Receptor Negative Recurrent or Persistent Endometrial Carcinoma

Trial Profile

A Phase II Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Progesterone Receptor Negative Recurrent or Persistent Endometrial Carcinoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Feb 2017

At a glance

  • Drugs Cridanimod (Primary) ; Medroxyprogesterone; Megestrol
  • Indications Endometrial cancer
  • Focus Therapeutic Use
  • Sponsors AS Kevelt
  • Most Recent Events

    • 23 Jan 2017 Status changed from recruiting to active, no longer recruiting.
    • 19 Aug 2016 According to Xenetic Biosciences media release, an Investigational New Drug (IND) application for the Company's product candidate, Virexxa (sodium cridanimod), has been allowed to proceed by the U.S. Food and Drug Administration (FDA).
    • 23 Jul 2015 Planned End Date changed from 1 Oct 2017 to 1 Jul 2018 as reported by ClinicalTrial.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top